Two hundred and thirteen patients were randomized in a 1:1 ratio to receive either s.c. injections of placebo from weeks 0 to 20 followed by golimumab 50 mg from weeks 24 to 48 ( group 1 , n = 105 ) or golimumab 50 mg from weeks 0 to 48 ( group 2 , n = 108 ) , both every 4 weeks .